Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
21
XCRT Quote, Financials, Valuation and Earnings
Last price:
$0.0100
Seasonality move
:
22.73%
Day range:
$0.0078 - $0.0088
52-week range:
$0.0061 - $0.0279
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.33x
P/B ratio:
--
Volume:
42.9K
Avg. volume:
81.8K
1-year change:
-59.95%
Market cap:
$3.8M
Revenue:
$2.2M
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Xcelerate, Inc. has -- downside to fair value with a price target of -- per share.
XCRT vs. S&P 500
-
Over the past 5 trading days, Xcelerate, Inc. has underperformed the S&P 500 by -11.42% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Xcelerate, Inc. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Xcelerate, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Xcelerate, Inc. reported revenues of $535.4K.
Earnings Growth
-
Xcelerate, Inc. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Xcelerate, Inc. reported earnings per share of --.
Enterprise value:
5.2M
EV / Invested capital:
--
Price / LTM sales:
3.33x
EV / EBIT:
--
EV / Revenue:
4.67x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-7.35x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | $766.3K | $535.4K | |
| Gross Profit | -- | -- | -- | $127.6K | $46.7K | |
| Operating Income | -- | -- | -- | -$248.1K | -$178.2K | |
| EBITDA | -- | -- | -- | -$209K | -$139.1K | |
| Diluted EPS | -$0.00 | -- | -- | -$0.00 | -$0.00 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $11.3K | -- | $858.3K | $764.7K | |
| Total Assets | -- | $121.3K | -- | $1.8M | $1.6M | |
| Current Liabilities | $45.4K | $271.1K | -- | $2.5M | $3.2M | |
| Total Liabilities | $45.4K | $271.1K | -- | $2.5M | $3.2M | |
| Total Equity | -$45.4K | -$149.8K | -- | -$657.2K | -$1.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$208.1K | $9.5K | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | $188.8K | -$27.5K | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
XCRT
Sector
Market Cap
$3.8M
$28.1M
Price % of 52-Week High
31.36%
50%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.54%
1-Year Price Total Return
-59.95%
-17.67%
Beta (5-Year)
0.778
0.503
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0098
200-day SMA
Sell
Level
$0.0161
Bollinger Bands (100)
Sell
Level
0.0137 - 0.0137
Chaikin Money Flow
Buy
Level
161.4M
20-day SMA
Sell
Level
$0.0105
Relative Strength Index (RSI14)
Sell
Level
37.0264
ADX Line
Sell
Level
63.8817
Williams %R
Neutral
Level
-53.5088
50-day SMA
Sell
Level
$0.0115
MACD (12, 26)
Sell
Level
-0.0008
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
232.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-9.0266)
Sell
CA Score
(Annual)
Level (-6.1911)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (15.5513)
Buy
Piotroski F Score
(Annual)
Level (4)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Xcelerate, Inc. is a medical company, which engages in the provision of acquiring intellectual property technology for medical applications. The company was founded on November 26, 1996 and is headquartered in Mauldin, SC.
Stock Forecast FAQ
In the current month, XCRT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The XCRT average analyst price target in the past 3 months is --.
-
Where Will Xcelerate, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Xcelerate, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Xcelerate, Inc.?
Analysts are divided on their view about Xcelerate, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Xcelerate, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is Xcelerate, Inc.'s Price Target?
The price target for Xcelerate, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is XCRT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Xcelerate, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of XCRT?
You can purchase shares of Xcelerate, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Xcelerate, Inc. shares.
-
What Is The Xcelerate, Inc. Share Price Today?
Xcelerate, Inc. was last trading at $0.0100 per share. This represents the most recent stock quote for Xcelerate, Inc.. Yesterday, Xcelerate, Inc. closed at $0.0088 per share.
-
How To Buy Xcelerate, Inc. Stock Online?
In order to purchase Xcelerate, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get XCRT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
XCRT
Sector
P/E ratio
--
23.88x
PEG ratio
--
-0.01x
P/B ratio
--
1.81x
Price / LTM sales
3.33x
1.59x
Growth Metrics
XCRT
Sector
Revenue growth
--
4.73%
Earnings growth
--
11.11%
Revenue (5-year growth)
--
6.46%
Earnings forecast
--
-$0.18
Profitability
XCRT
Sector
Profitability FY 2024
$333.6K
$3.6M
Return on invested capital
--
-31.77%
Return on assets
--
-28.18%
Return on equity
--
-37.47%
Earnings Date
Last Earnings Date
Jan
1
Next Earnings Date
Jan
1
Estimated Next Earnings Date
Apr
2
Balance Sheet
XCRT
Sector
Total cash
$75.1K
$26.3M
Short term investments
--
$26M
Total assets
$1.7M
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Buy
81
ZIJMY alert for Jan 1
Zijin Mining Group Co., Ltd. [ZIJMY] is up 1.86% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
